Intuitive Surgical today announced multiple executive position changes within the company effective immediately. Dave Rosa, who previously served as executive vice president and chief strategy and growth officer, has been promoted to the role of president and will lead the company’s product, digital, quality, regulatory, supply chain, manufacturing, and commercial teams.

“Aligning our core business functions under [Rosa], a proven and outstanding leader with broad and deep experience across Intuitive, equips us to meet future opportunities to collaborate with hospitals and healthcare systems to address healthcare challenges at significant scale,” Gary Guthart, Intuitive CEO, said.

A 27-year company veteran, Rosa previously held leadership positions across the minimally invasive robotic-assisted surgery company’s commercial, engineering, clinical development, marketing, and product development organizations. “Our efforts over the past 27 years have created great opportunities to serve our customers better and in new ways. I look forward to leading our continued development of innovative, outcomes-focused products, services, and solutions,” Rosa said. “Intuitive aims to deliver excellence in customer experience, industry-leading innovation, and meaningful expansion of minimally invasive care. My goal is to help the company continue to deliver on these aims.”

Bob DeSantis will move into the newly created role of executive vice president and chief strategy and corporate operations officer. In the position, he will lead strategic planning, operational structure, and management of the business. In his 10 years at the company, he has helped advance the development and manufacture of robotic platforms and served as executive vice president and chief product officer.

Guthart continues as Intuitive’s CEO, as he has since 2010, with both Rosa and DeSantis reporting to him. Guthart, according to the company, will continue to lead and focus on the company’s presence in the market, as well as look over its overall strategy, governance, and culture, while nurturing early-stage business and product initiatives.

“As Intuitive has grown and demand for robotic-assisted surgery has increased, we remain focused on our mission to advance minimally invasive care and our commitment to working with customers to meaningfully improve patient outcomes,” he said.

The change in executive positions follow a line of other news from the company in 2023, including its decision to not launch a next-generation multiport system this year. Additionally, Intuitive obtained new urological indications from FDA to market the da Vinci SP for simple prostatectomy as a representative procedure and for transvesical approach to simple and radial prostatectomy. Intuitive also won a CE mark for its Ion system.

Regarding first-quarter earnings, Intuitive reported strong procedure growth in Q123.

"We saw surprising strength in the quarter led by general surgery in the United States and procedure growth beyond urology outside the United States. On a procedure basis, cholecystectomy, bariatric surgery and hernia repair led the way," said Guthart, during the company's first-quarter earnings call, according to Seeking Alpha transcripts.

The company was also recently named 24th on MD+DI’s annual Top 40 Medical Device Companies, down one spot from last year’s list.